Curative Proton Therapy for Infants: At What Cost?

D. Indelicato , J. Bradley , D. Klawinski , P. Aldana , E. Sandler , C. Morris , R. Mailhot
{"title":"Curative Proton Therapy for Infants: At What Cost?","authors":"D. Indelicato ,&nbsp;J. Bradley ,&nbsp;D. Klawinski ,&nbsp;P. Aldana ,&nbsp;E. Sandler ,&nbsp;C. Morris ,&nbsp;R. Mailhot","doi":"10.1016/j.ijrobp.2024.11.017","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Infants (age 12 months and younger) are the most difficult population of cancer patients to treat. Historically, radiation would be excluded from treatment options and this view remains prevalent worldwide. New radiation technology may shift this perspective. The purpose of this study is to report the outcomes of infants undergoing treatment with curative-intent proton therapy.</div></div><div><h3>Methods</h3><div>Between 2006-2023, 15 infants with a median age of 11 months (range, 7-12 months) were irradiated at the University of Florida, constituting 0.75% of all pediatric patients treated with curative intent during this period. Eight patients were male and none had metastatic disease. The diagnoses included rhabdomyosarcoma (7), Ewing sarcoma (2), ATRT (1), ependymoma (1), and pineoblastoma (1). All patients were treated with standard radiation doses for their disease and the mean was 50.4 GyRBE (range, 41.1-54). 14/15 patients received disease-specific multi-agent chemotherapy. Cumulative incidence method was used to estimate overall survival (OS), cause-specific survival (CSS), progression-free survival (PFS), and local control (LC).</div></div><div><h3>Results</h3><div>With a median followup of 3.5 years (range, 01.-11.2 years), the 5 year OS, CSS, PFS, and LC was 58%, 65%, 58%, and 72%, respectively. Two and 5 patients had leptomeningeal and local recurrence, respectively. One patient died from a 1 metachronous rhabdoid tumor in lungs and kidneys. No patients were lost to follow-up. Four of 7 surviving patients experienced serious toxicity including blindness, deafness, vasculopathy and cataracts requiring surgery, global developmental delay, panhypopituitarism, hemorrhagic cystitis, and severe dentofacial and musculoskeletal problems.</div></div><div><h3>Conclusion</h3><div>When proton therapy is utilized as part of a multimodality treatment plan in infants with sarcoma and brain tumors, survival is possible but often comes at the cost of major toxicity. Improvements in patient selection may take us farther than improvements in technology.</div></div>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"121 3","pages":"Page e3"},"PeriodicalIF":6.4000,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0360301624035910","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

Infants (age 12 months and younger) are the most difficult population of cancer patients to treat. Historically, radiation would be excluded from treatment options and this view remains prevalent worldwide. New radiation technology may shift this perspective. The purpose of this study is to report the outcomes of infants undergoing treatment with curative-intent proton therapy.

Methods

Between 2006-2023, 15 infants with a median age of 11 months (range, 7-12 months) were irradiated at the University of Florida, constituting 0.75% of all pediatric patients treated with curative intent during this period. Eight patients were male and none had metastatic disease. The diagnoses included rhabdomyosarcoma (7), Ewing sarcoma (2), ATRT (1), ependymoma (1), and pineoblastoma (1). All patients were treated with standard radiation doses for their disease and the mean was 50.4 GyRBE (range, 41.1-54). 14/15 patients received disease-specific multi-agent chemotherapy. Cumulative incidence method was used to estimate overall survival (OS), cause-specific survival (CSS), progression-free survival (PFS), and local control (LC).

Results

With a median followup of 3.5 years (range, 01.-11.2 years), the 5 year OS, CSS, PFS, and LC was 58%, 65%, 58%, and 72%, respectively. Two and 5 patients had leptomeningeal and local recurrence, respectively. One patient died from a 1 metachronous rhabdoid tumor in lungs and kidneys. No patients were lost to follow-up. Four of 7 surviving patients experienced serious toxicity including blindness, deafness, vasculopathy and cataracts requiring surgery, global developmental delay, panhypopituitarism, hemorrhagic cystitis, and severe dentofacial and musculoskeletal problems.

Conclusion

When proton therapy is utilized as part of a multimodality treatment plan in infants with sarcoma and brain tumors, survival is possible but often comes at the cost of major toxicity. Improvements in patient selection may take us farther than improvements in technology.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.00
自引率
7.10%
发文量
2538
审稿时长
6.6 weeks
期刊介绍: International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field. This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.
期刊最新文献
Moving from the background towards the spotlight: A critical review of radiation therapy for locally advanced pancreas cancer. A Pilot Study of CT Simulator Downtime at an African Cancer Conference: Survey Results from AORTIC 2023. Regional Near-surface Dose Predicts Moist Desquamation and Implant Failure in Patients Receiving Radiation Therapy for Breast Cancer. Boswellia serrata for cerebral radiation necrosis after radiosurgery for brain metastases. Development and validation of a prediction model for cardiac events in patients with hepatocellular carcinoma undergoing stereotactic body radiation therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1